The m6A modification mediated-lncRNA POU6F2-AS1 reprograms fatty acid metabolism and facilitates the growth of colorectal cancer via upregulation of FASN

• Published in: Molecular cancer Vol. 23; no. 1; pp. 1 - 55
• Main Authors: Jiang, Tao, Qi, Junwen, Xue, Zhenyu, Liu, Bowen, Liu, Jianquan, Hu, Qihang, Li, Yuqiu, Ren, Jing, Song, Hu, Xu, Yixin, Xu, Teng, Fan, Ruizhi, Song, Jun
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 16.03.2024; BioMed Central; BMC
• Subjects: Analysis; Bioinformatics; Cell culture; Chemotherapy; Colorectal cancer; Colorectal carcinoma; Enzymes; Fatty acid metabolism; Fatty acids; Growth; Health aspects; Life sciences; Lipids; Lipogenesis; Liquid chromatography; Mass spectrometry; Mass spectroscopy; Medical prognosis; Metabolism; Methyltransferases; N6-methyladenosine; Non-coding RNA; Organoids; Patients; POU6F2-AS1; Proteins; RNA; RNA polymerase; Therapeutic targets; Transcription activation; Triglycerides; Tumorigenesis; Up-regulation; China; Beijing China; United States > US
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/s12943-024-01962-8

Abstract Background Long noncoding RNAs (lncRNAs) have emerged as key players in tumorigenesis and tumour progression. However, the biological functions and potential mechanisms of lncRNAs in colorectal cancer (CRC) are unclear. Methods The novel lncRNA POU6F2-AS1 was identified through bioinformatics analysis, and its expression in CRC patients was verified via qRT–PCR and FISH. In vitro and in vivo experiments, such as BODIPY staining, Oil Red O staining, triglyceride (TAG) assays, and liquid chromatography mass spectrometry (LC-MS) were subsequently performed with CRC specimens and cells to determine the clinical significance, and functional roles of POU6F2-AS1. Biotinylated RNA pull-down, RIP, Me-RIP, ChIP, and patient-derived organoid (PDO) culture assays were performed to confirm the underlying mechanism of POU6F2-AS1. Results The lncRNA POU6F2-AS1 is markedly upregulated in CRC and associated with adverse clinicopathological features and poor overall survival in CRC patients. Functionally, POU6F2-AS1 promotes the growth and lipogenesis of CRC cells both in vitro and in vivo. Mechanistically, METTL3-induced m 6 A modification is involved in the upregulation of POU6F2-AS1. Furthermore, upregulated POU6F2-AS1 could tether YBX1 to the FASN promoter to induce transcriptional activation, thus facilitating the growth and lipogenesis of CRC cells. Conclusions Our data revealed that the upregulation of POU6F2-AS1 plays a critical role in CRC fatty acid metabolism and might provide a novel promising biomarker and therapeutic target for CRC.